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Abstract: The treatment of chronic lymphocytic leukemia (CLL) has evolved over the past decade. Our better understanding of disease 
biology and risk stratification has allowed delivering more effective therapies. In fact, front-line chemoimmunotherapy has demon-
strated improvement in overall survival when compared to chemotherapy in randomized studies. Yet, treatment of relapsed CLL remains 
challenging and few agents are effective in that setting. Ofatumumab (Ofa) is a humanized monoclonal antibody targeted against CD20 
with demonstrable activity in rituximab-resistant CLL cell lines. This agent was recently approved for the treatment of relapsed/refrac-
tory CLL patients who have failed fludarabine and alemtuzumab. In this review, we provide a historical perspective on approaches to 
CLL as front-line and in the relapsed setting. We further summarize novel anti-CD20 antibodies with specific emphasis on ofa. We 
review studies that led to ofatumumab’s approval including pre-clinical data, trials using ofa in combination therapies, and adverse 
events/toxicities reported with this agent.
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Introduction
Chronic lymphocytic leukemia (CLL) is characterized 
by  the  progressive  accumulation  of  phenotypically 
mature malignant lymphocytes likely a combination 
of predominant resistance to apoptosis and a compo-
nent of continuing proliferation.1 CLL cells usually 
co-express CD5, CD23, CD19, CD79b and CD20, but 
the level of expression of CD20, CD79b, and surface 
immunoglobulin  is  low  compared  to  normal  B 
  lymphocytes.1 The International Working Group for 
CLL  (IWCLL)  has  clarified  that  the  presence  of 
5000  monoclonal  B  lymphocytes/µl  is  required  to 
diagnose  CLL  rather  than  5000/µl    lymphocytes; 
emphasizing the importance of demonstrating clonal-
ity to establish the diagnosis.2 In   addition, the IWCLL 
formally  recognized  monoclonal  B  lymphocytosis 
(MBL); an entity characterized by less than 5000 mono-
clonal lymphocytes/µl in the blood; with an annual 
risk of progression to CLL of 1%–2%.2
Our  understanding  of  CLL  biology  has  evolved 
rapidly allowing us to divide CLL into unfavorable 
high-risk and favorable low-risk disease.3 The novel 
prognostic indicators that allowed this division recog-
nize the differences in disease behavior and prognosis 
within each clinical stage raising the question as to 
whether our current clinical staging system needs to 
be revised. Characteristically, patients with unfavor-
able CLL carry the unmutated IgVH,4 have over 20% 
of  malignant  cells  expressing  the  zeta-associated 
tyrosine kinase protein (ZAP-70),5 with $30% of cells 
expressing CD38 by flow cytometry,6 and have adverse 
genomic aberrations generally defined as 17p and 11q 
deletions.7 These latter patients respond less well to 
our best therapies and responding patients have higher 
risk of relapsing more quickly and dying from the 
disease.8–10
While we have made substantial strides in finding 
aggressive combination chemotherapies and chemoim-
munotherapy regimens (CIT) that have substantial activ-
ity in the front-line setting,11 our ability to treat relapsed 
or  refractory  disease  has  been  limited.  Patients  with 
relapsed disease are frail, demonstrate poor performance 
status, their disease is usually resistant to standard che-
motherapy, their immune system precludes aggressive 
measures, and they frequently carry unfavorable prog-
nostic features.12 Despite higher response rates and pro-
longed disease-free intervals when CIT is implemented 
in front-line CLL, there is no agreed upon standard as to 
the most effective therapy in relapsed disease especially 
in older patients where allogeneic stem cell transplanta-
tion is not an option. Accordingly, the need for active 
agents in this adverse clinical setting is urgent. In this 
article,  we  briefly  review  the  evolution  of  treatment 
  paradigms in CLL, discuss the importance of targeted 
therapies and in particular focus on monoclonal anti-
bodies specific for CD20 antigen (Fig. 1) as the target-
ing of this receptor has made a large difference in our 
overall responses including complete remission rates 
in CLL. We describe clinical trials that led to the novel 
anti-CD20  monoclonal  antibody  ofatumumab’s 
approval in relapsed CLL, and suggest future   directions. 
This review is timely in that newer therapies are now 
being designed specifically for patients with relapsed/ 
refractory disease where choices of therapy are typi-
cally limited and responses are short-lived.
Historical perspective  
of Up-Front Therapy
Recent advances in combination chemotherapies and 
the identification of highly effective membrane recep-
tor targeted monoclonal antibodies have allowed the 
introduction of effective regimens with high remission 
rates and better potential of eradicating disease to very 
low levels. The first major advance in modern treat-
ment of CLL was the demonstration that purine ana-
logues provided patients with better complete remission 
(CR) rates, improved progression-free survival (PFS), 
and  recently  better  overall  survival  (OS)  compared 
with  alkylating  agents.13,14  Fludarabine  (F)  was  the 
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Figure  1.  CD20  molecule  and  the  binding  sites  of  rituximab  and 
ofatumumab. 
Reprinted with permission © 2008 American Society of Clinical Oncology. 
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purine  analogue  most  commonly  studied  although 
other analogues (pentostatin and cladribine) have well 
documented and substantial activity in this disease.15,16 
The paradigm that F inhibits the repair of alkylating-
agent induced DNA interstrand crosslinks that enable 
leukemic cells to overcome the cytotoxic effects of 
alkylating agents provided the rationale to combine F 
with  cyclophosphamide  (C).17  Three  prospectively 
designed randomized studies have clearly shown the 
superiority of FC combination compared to F mono-
therapy making FC the most robust combination che-
motherapy  regimen  in  upfront  CLL  therapy.18–20 
FC provided patients with high CR rates (24%) and 
prolonged PFS (30–48 months) although OS was not 
better than F monotherapy. With the knowledge that 
monoclonal antibodies have an impact on the leukemic 
burden in CLL, combining chemotherapy with CD20 
directed agents was the next logical step. The first sug-
gestion  that  chemoimmunotherapy  (CIT)  might 
improve the outcome in CLL was reported by Byrd 
et al when the combination of F with rituximab (R) 
demonstrated high response rates, CR, and PFS com-
pared to F alone or to the sequential program of F fol-
lowed  by  R.21,22  Subsequently,  the  regimen  of  FCR 
(fludarabine, cyclophosphamide, and rituximab) pio-
neered by Keating et al showed unprecedented overall 
response (OR) rates (95%, CR 72%) with some patients 
attaining molecular remissions that amounted to truly 
negligible levels of leukemia burden.23 However, other 
CIT combinations showed similar OR, specifically the 
PCR (pentostatin, cyclophosphamide, and rituximab) 
and FCR-Lite (attenuated doses of FCR with mainte-
nance rituximab).24,25 While the OR rates were similar 
between FCR and PCR, the CR rate favored FCR. 
However, it was suggested that PCR might be better 
tolerated in patients with advanced age, renal dysfunc-
tion,  or  elevated  beta-2-microglobulin.26  This  latter 
aspect is not trivial as the mean age of CLL patients in 
this country is around 70 with higher prevalence of 
renal dysfunction in the older cohort.
Recently, the German CLL Study Group (GCLLSG) 
reported on a randomized phase III study comparing 
FCR to FC. With a median follow up of 38 months, 
the OR favored FCR (95% vs. 88%, P = 0.001) with 
better  CR  rates  (44%  vs.  22%,  P  ,  0.001).11 
  Importantly, PFS was superior in the FCR arm (52 vs. 
33 months, P , 0.001) with more patients alive at 
37 months in the FCR arm (84% vs. 79%, P = 0.01). 
Of interest, however, this GCLLSG trial has only had 
a CR level in the low 40% range likely reflecting the 
community-based cohort rather than referral popula-
tions seen with the earlier phase 2 studies. This study 
justified implementing FCR as the standard front-line 
approach in young, fit patients where there is typi-
cally little comorbidity.27
Treatment of Relapsed and Refractory   
Disease
There is no universally agreed upon standard approach 
to patients with relapsed or refractory disease. While 
some benefit from second line therapy initially, others 
require aggressive measures and stem cell transplan-
tation.28  Furthermore,  the  fact  that  most  relapsed/
refractory patients carry resistant clones and demon-
strate  aggressive  biologic  features  makes  selecting 
the appropriate therapy a truly challenging endeav-
or.29 To a certain extent this has been made easier by 
two antibodies specific for CD52 and CD20. The fol-
lowing discussion lists several treatment options for 
the relapsed/refractory CLL cohorts but does not nec-
essarily imply our hierarchy of choices for this patient 
population.
Alemtuzumab is a humanized monoclonal antibody 
that  targets  CD52  with  notable  clinical  activity  in 
CLL. Keating et al reported an OR of 33% with 2% 
CR  in  93  heavily  pretreated  CLL  patients.30  The 
median OS was 16 months for the entire population 
and 32 months for responders; an outcome that com-
pares  favorably  with  the  reported  median  OS  of 
10  months  in  comparable  albeit  historical  control 
patients.31 The activity of R alone in relapsed/  refractory 
CLL has been marginal and remissions were partial 
and of short duration making this antibody a less ideal 
monotherapy  for  this  cohort.32  Combining  alemtu-
zumab  with  R  has  been  explored  in  the  relapsed/
refractory33,34 setting with some activity that led to fur-
ther  development  of  this  regimen  in  the  upfront 
approaches.35,36 It is important, however, to note that 
we have learned that not all patients are appropriate 
for alemtuzumab treatment as it is less effective in 
patients with bulky nodal disease (.5 cm).30 In fact, 
Tam et al reviewed the outcome of 99 patients who 
were F-refractory and ineligible or refractory to alem-
tuzumab.37 The OR to first salvage therapy other than 
transplantation was 23%, with no CRs. Early death 
(within 8 weeks of commencing first salvage) occurred Nabhan and Kay
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in 13% of patients, and 54% of patients experienced a 
major infection during therapy while OS was 9 months. 
These poor results highlight the urgent need for effec-
tive therapeutic agents in this clinical setting.
To improve upon those results and given the well 
documented activity of CIT in front-line, several stud-
ies  investigated  several  CIT  programs  in  relapsed 
  disease. While phase II studies conducted in that set-
ting were mainly single institution with diverse patient 
population demographics, all have suggested better 
outcomes for OR and CR when compared to single 
agent chemotherapies. FCR was studied in relapsed 
disease  with  patients  achieving  a  CR  levels  from 
15%–25%.38 Subsequently, a phase III randomized 
study compared FCR to FC confirming superiority of 
the former in terms of OR (70% vs. 58% P = 0.003), 
CR  (24%  vs.  13%,  P  ,  0.001),  and  PFS  (31  vs. 
21 months, P , 0.001).39 OS, however, was not found 
to be different although long-term follow-up might 
yet prove otherwise.
Other CIT combinations have been explored in the 
relapsed setting. The combination of F with alemtu-
zumab has been reported with CR rates .30%.40 In 
addition, the combination of FCR plus alemtuzumab 
has been proven safe, effective, and able to overcome 
high-risk disease.41 However, when given as a con-
solidative approach in CR patients treated front-line 
with FR, alemtuzumab has been associated with seri-
ous adverse events and has recently been shown to 
increase infectious complications risks and death.42 
Table 1 summarizes the pivotal CIT protocols com-
monly used in relapsed/refractory disease.
cD20
One approach to improve on our current therapeutics 
for  relapsed/refractory  disease  is  to  optimize  our 
targeted  approach  to  CLL  B  cell  membrane 
antigens/receptors. While the ideal receptor would 
be only on CLL B cells the CD20 receptor is at least 
restricted to B lymphocytes. CD20 is a transmem-
brane glycoprotein that is expressed on B-cells spar-
ing  the  stem  cells.43  While  the  exact  role  of  this 
antigen in B cell development and function is not 
clear, experimental data suggested that it has a role in 
B-cell activation, transmembrane calcium flux, and 
regulation  of  B-cell  growth  a  proliferation.44  The 
therapeutic appeal of CD20 as a target for therapy is 
that it is not internalized or downregulated after anti-
body binding. Antibody/antigen interaction also can 
theoretically allow for direct cell kill and cytotoxic-
ity (ADCC).45 Of interest the CD20 expression level 
in CLL B cells is lower than other malignant or nor-
mal B cells. The low level of CD20 expression in 
CLL likely explains the minimal activity of R as a 
single agent in this setting although such activity was 
enhanced when the drug was given more frequently 
(thrice/weekly)46  or  at  much  higher  doses 
(.2000 mg/m2 for each infusion).47 Given its known 
single  agent  activity,  theoretical  multiple  killing 
functions and known efficacy in CIT, the strategy of 
developing and testing novel monoclonal antibodies 
that target the CD20 molecule has become an active 
strategy. See Figure 1 for more detail on the binding 
sites for both rituximab and the humanized antibody 
ofatumumab discussed below.
Rituximab
Rituximab is a chimeric anti-CD20 monoclonal anti-
body with remarkable activity in B-cell lymphoma. 
However, its activity in relapsed CLL is modest at 
standard doses; around 12% response.48 This limited 
activity may be due to faint CD20 expression in CLL, 
Table 1. Select chemotherapy or CIT in the treatment of relapsed/refractory CLL.
Regimen n OR cR RD (months) comments
FCR39 276  70% 24% 31 R is given at 500 mg/m2
PCR71 32 75% 25% 25 25% of patients were F-refractory
FA40 36 83% 31% 13 A given for 3 days every 28-days. Treatment for 6 cycles
BR72 81 77% 15% NR Median number of prior therapies was 2
FCR + L73 31 65% 52% 29 Trial comparing FCR vs. FCR + L is underway
FC39 276 58% 13% 13 This was the inferior arm against FCR in the randomized ReACH trial
Abbreviations: FCR, fludarabine, cyclophosphamide, and rituximab; OR, overall response; CR, complete response; RD, response duration; R, rituximab; 
PCR, pentostatin, cyclophosphamide, and rituximab; F, fludarabine; FA, fludarabine plus alemtuzumab; A, alemtuzumab; BR, bendamustine plus rituximab; 
NR, not reported; L, lumiliximab; FC, fludarabine plus cyclophosphamide.Ofatumumab in CLL
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and from CD20 acting as a decoy receptor or being 
present in soluble form in the plasma. However, the 
use  of  rituximab  at  higher  doses  or  with  greater 
frequency results in higher response rates as mentioned 
above.46,47 Most studies of rituximab in relapsed CLL 
show  that  the  duration  of  response  is  only  a  few 
months.49,50 When rituximab is used alone as frontline 
therapy,  higher  response  rates  are  seen  with  longer 
durations of response. However, most of these studies 
included heterogeneous patient populations including 
low-grade lymphoma, and most frontline trials included 
maintenance  therapy;  making  the  interpretation  of 
clinical  activity  difficult.51,52  Rituximab  is  relatively 
safe in CLL, with infusion-related reactions being the 
most common adverse events seen albeit some of these 
reactions are robust. No increased in infectious com-
plications have been reported although there are reports 
of reactivation of hepatitis B or JC virus.53,54 In addi-
tion, clinicians need to be vigilant to the “black box” 
warning regarding hepatitis B reactivation. Discussing 
all data pertaining to rituximab in CLL is beyond the 
scope of this review as our main focus in this review is 
the newer anti-CD20 antibodies.
select Anti-cD20 Antibodies  
excluding Rituximab (Table 2)
Obinutuzumab
This is a humanized antibody that binds with high 
affinity and selectivity to the extracellular domain of 
the human CD20 antigen on B cells.55 While ritux-
imab  recognizes  type  1  epitope,  obinutuzumab 
recognizes the type II epitope localized in the extra-
cellular loop of CD20. In addition, the Fc-region of 
this  antibody  was  glycoengineered  to  contain 
bisected,  fucosylated  carbohydrates  allowing  for 
increased affinity to the FcyRIII [a] allowing for bet-
ter antibody-dependent cellular cytotoxicity (ADCC), 
direct cell kill, and apoptosis.56 Salles et al conducted 
a phase I/II study with this antibody in 24 patients 
with CD20+ lymphoid malignancies confirming its’ 
safety  and  activity.57  Of  those  patients,  13  had 
relapsed/refractory CLL, of which 11 were   evaluable. 
Seven patients exhibited a clinical response despite 
prior  rituximab  therapy.  Subsequently,  a  phase  I 
study was conducted in 13 refractory CLL patients 
(33% with high-risk cytogenetics). Here, even in a 
difficult high risk clinical cohort, the OR was 62% 
with transient neutropenia being the most common 
adverse event.58
veltuzumab
Veltuzumab is a unique and well crafted second-
generation humanized anti-CD20 monoclonal anti-
body  that  contains  90%–95%  human  antibody 
sequences with identical antigen framework regions 
to  epratuzumab  (the  humanized  anti-CD22)  and 
similar antigen-binding determinants to rituximab.59 
In vitro studies have demonstrated that veltuzumab 
has enhanced binding avidity and a stronger effect 
on complement-dependent cytotoxicity (CDC) com-
pared with rituximab in selected cell lines.60 Clinical 
trials of this agent are underway.
Table 2. Current anti-CD20 monoclonal antibodies.1
Antibody and  
trial phase
Type MOA clinical data comments
Rituximab (approved) Chimeric ADCC, CDC, 
and apoptosis
Activity minimal as 
monotherapy
Enhanced efficacy when 
combined with chemotherapy
Ofatumumab 
(approved/phase III)
Humanized CDC more 
pronounced
Active in F and alemtuzumab 
refractory or in F refractory  
and bulky disease (.5 cm)
To date, no known  
enhancement in CIT activity
veltuzumab 
(phase I/II)
Humanized Less apoptotic 
effects
Clinical trials are pending
Obinutuzumab 
(phase I)
Humanized ADCC more 
pronounced
Responses noted in high-risk 
cytogenetic patients  
and refractory setting
Myelosuppression is the  
most common toxicity
Ocrelizumab 
(phase I/II)
Humanized ADCC more 
pronounced
PFS was 11.4 months in 
refractory FL patients
Infusion-related toxicities are  
the most common
note: Current implies either approved for use or is being studied in clinical trials.
Abbreviations:  MOA,  mechanism  of  action;  CDC,  complement  dependent  cytotoxicity;  ADCC,  antibody  dependent  cellular  cytotoxicity;   
CIT, chemoimmunotherapy; F, fludarabine; PFS, progression-free survival; FL, follicular lymphoma.Nabhan and Kay
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Ofatumumab
Ofatumumab (Ofa) is a human type 1 IgG antibody 
that binds a segment of CD20 that contains the small 
extra-cellular loop along with the N-terminal region 
of the second large extra-cellular loop.61 Ofa exhibits 
a multiplicity of activity via CDC, ADCC, and has 
shown  enhanced cell killing  in rituximab-resistant 
cell lines.62 It is hypothesized that enhanced CDC 
demonstrated with Ofa is related to its closer binding 
to the cell membrane.61,62 Using a mouse xenograft 
model, Bleeker et al evaluated the optimal dose of 
Ofa required to sustain in-vivo activity.63 The authors 
demonstrated that B-cell repopulation occurred when 
serum  Ofa  levels  dropped  below  10  mcg/ml  and 
accordingly  sustaining  these  levels  might  enhance 
activity. Coiffier et al reported a phase I/II study in 
relapsed/refractory CLL with an OR of 50%, but the 
median  response  duration  was  only  3.7  months.64 
However,  median  duration  to  next  treatment  was 
12 months. Subsequently, an international phase II 
study of 138 CLL patients with double refractory 
disease (that is refractory to fludarabine and alemtu-
zumab; n = 59) or those that were refractory to flu-
darabine with bulky (.5 cm) lymphadenopathy (here 
alemtuzumab was deemed a less viable option due to 
sizable lymphadenopathy [n = 79] was   conducted.65 
The OR was 47%–58% with a median PFS of 5.7–
5.9 months and median OS of 13.7–15.4 months. The 
drug  was  tolerated  well,  but  a  25%  incidence  of 
infectious  complications  was  reported.65  These 
impressive clinical results in very high risk CLL led 
to its recent approval by the FDA for fludarabine- 
refractory disease and patients who have failed trials 
of alemtuzumab.
Österborg et al evaluated the relationship between 
baseline characteristics and pharmacokinetics (PK) data 
in patients enrolled onto this pivotal study.66 Treated 
patients received 8 weekly infusions of Ofa followed by 
4 monthly infusions (Dose 1, 300 mg; Doses 2–12, 
2000 mg). Blood samples for PK analysis were col-
lected at Dose 1, Dose 8, and Dose 12. The relation-
ships between baseline patient characteristics, disease 
factors, and PK parameters were evaluated by multi-
variate regression analysis. Associations between PK 
and OR/PFS were also explored using univariate and 
multivariate logistic regression or Cox regression anal-
yses.66  This  analysis  showed  that    factors  reflecting 
disease  burden  such  as  bone    marrow  involvement  or 
elevated serum   beta-2-  microglobulin levels affect Ofa 
PK  levels  and  that  high  serum  concentrations  after 
doses  8  and  12  were  associated  with  improved 
outcome.
This  latter  study  should  provide  guidelines  for 
future studies with Ofa in the high risk and high dis-
ease burden CLL patient.
Ofa in combination Therapies
The impressive clinical response data demonstrated 
with FCR and the clinical as well as theoretical advan-
tage for Ofa over R based on the former CD20 directed 
agent’s functional activity, paved the way to a multi-
center  phase  II  study  combining  FC  with  Ofa. 
Wierda et al conducted a randomized phase II study 
using two dose schedules of Ofa in combination with 
FC; the so-called O-FC regimen (30 patients received 
Ofa at 100 mg and 31 patients at 500 mg).67   Treatment 
was repeated every 4 weeks for a total of 6 courses in 
chemotherapy-naïve  CLL.  OR  rates  were  77% 
(CR 32%) and 73% (CR 50%) for the low-dose and 
high-dose respectively. While these rates appear infe-
rior to the historical phase II FCR remission rates, 
they are actually somewhat comparable to what has 
been reported by the GCLLSG in the FCR vs. FC ran-
domized study. This is likely due to the fact that this 
study was a community based study reflecting the 
typical patient response to this CIT.   Myelosuppression 
was the most common toxicity in this   combination. 
Other important studies are underway including Ofa 
with pentostatin, Ofa/alemtuzumab regimen, Ofa and 
lenalidomide, and Ofa/bendamustine.68
Toxicity and Adverse events
Ofa  has  been  well-tolerated  with  infusion-related 
adverse events being the most commonly reported. 
Most side effects occur on the day of infusion and are 
of grades 1 or 2. These are generally fevers, chills, 
shortness of breath, rash, and urticaria. Most infusion-
related events occur with the first infusion and sub-
side with further treatment doses.64,69
Coiffier  et  al  observed  grade  3  hepatitis  in  one 
patient although it remains questionable whether such 
event was Ofa-related.64 Other severe adverse events 
included herpes zoster in one patient and fatal intersti-
tial  lung  disease  in  another.  Only  12%  of  patients Ofatumumab in CLL
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experienced grade 3 or worse infectious complications 
although no significant drop in serum immunoglobu-
lin levels was seen. Grade 3 or 4 hematologic toxicity 
was witnessed in 15% of patients with 6% having 
grade 3 or 4 neutropenia.70
conclusions
The activity of CIT in CLL in front-line and relapsed 
disease has clearly improved the overall outlook and 
outcome  for  patients  with  this  disease.  Refractory 
patients, however, have limited therapeutic options 
due to acquired drug resistance and the presence of 
high risk features. We believe that taking advantage 
of the membrane receptors more or less restricted to 
the leukemic B cell is an excellent target for continu-
ing development to monoclonal antibodies like Ofa 
and future clinical trial evaluations in CLL. To this 
point, the hematology community is seeing that the 
novel CD20 directed antibody, Ofa, can be highly 
effective in high risk CLL patient populations with 
acceptable  toxicity  profile.  This  activity  has  been 
demonstrated  as  a  single  agent  and  will  likely  be 
enhanced when it is combined in correct dose and 
schedules with other targeted therapies or with aggres-
sive chemotherapy combinations. The ever changing 
landscape  of  CLL  therapeutics  is  eagerly  awaiting 
further  studies  with  unique  monoclonal  antibodies 
that target the CD20 membrane receptor.
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